Introduction
Datamonitor expects the antihypertensive market to exceed $50bn by 2014 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to be savvy regarding marketing and pricing structures for their products, as only the most cunning and aggressive companies look set to survive.
Scope
- Event-driven sales forecasts, for the period 2005-14, for the US, Japan, France, Germany, Italy, Spain and the UK, along with a global overview
- Discussion of individual products in four main classes; beta blockers (BBs), CCBs, ACE inhibitors and the ARBs
- Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches
- Commercial impact case studies on R&D innovation, clinical trial data and European healthcare reform
Highlights
The ARBs are now the most prescribed class of antihypertensives, as aggressive marketing and premium-pricing enables manufacturers to deliver strong growth in a highly genericized market. Post-2009, however, the value of the ARB class is set to flatten on the back of generic erosion and indication expansion for the ARBs as a class.
In order for companies to achieve and maintain growth in this sector, companies need to be savvy regarding the impact of healthcare reform across the globe, particularly in Europe, with marketers who are charged with selling drugs across the EU needing to challenge the attitude that Europe is one, uniform, market like the US and Japan.
Novartis’ SPP100 (aliskiren) looks set to become the first innovative treatment for hypertension in over a decade. However, due to concerns regarding premium-pricing and similar efficacy compared to the ARBs, market penetration is expected to be slow in the short-term until strong cardiovascular outcome data for the class becomes available.
Reasons to Purchase
- Access independent, event-driven forecasts for key antihypertensive products and classes across the seven major markets
- Assess the potential impact of clinical trial results, EU healthcare reform and new product launches on the antihypertensive market
- Gain insight into the antihypertensive market via up-to-date thought-leader opinions and gold-standard IMS Health sales data
CHAPTER 1 EXECUTIVE SUMMARY 3
Objective of the analysis 3
Datamonitor insight into the hypertension market 4
CHAPTER 2 MARKET DEFINITION AND OVERVIEW 11
Market definition and overview for this report 11
Hypertension 12
Disease overview 12
Epidemiology 13
Treatment options; the antihypertensive drug classes 15
Drugs that inhibit the renin-angiotensin system (RAS) 16
Drugs that do not inhibit the renin-angiotensin system (RAS) 31
Other classes of antihypertensive drugs 33
CHAPTER 3 COUNTRY MARKET ASSESSMENTS 35
Current and future opportunities and threats in the antihypertensives market 35
The global market: overview, opportunities and threats 35
Overview 35
National markets 41
The global movers and shakers 43
Global opportunities 44
Global threats 54
US market: overview, opportunities and threats 54
Overview 54
US market issues 56
Japan: overview, opportunities and threats 67
Overview 67
Japanese market issues 69
European Union: overview, opportunities and threats 79
Overview 79
EU market issues 82
CHAPTER 4 FORECAST ANALYSIS 88
Assumptions and events 88
Ongoing trends 88
Increasing market size 88
Increasing use of fixed-dose combinations 88
Trial results 88
New product launches 91
S-amlodipine 91
SPP100 (aliskiren) 92
Caduet 92
Patent issues 93
ARB patent expiries 94
CCB patent expiries 95
Beta-blocker patent expiries 96
ACE inhibitor patent expiries 96
Other patent expiries 96
Additional indications 97
Irbesartan gains congestive heart failure indication 98
Valsartan gains additional diabetes indication 99
Methodology 99
Forecasts 99
CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES 100
Introduction 100
Case study 1 100
Novartis and the "renin revolution" 100
Case study 2 113
Clinical trial data and the potential to change prescribing habits 113
Case study 3 122
EU healthcare reforms: a tale of two countries 122
APPENDIX A – MARKET DATA AND MAJOR BRAND KEY FACTS 134
Global hypertension market data 134
Major brand facts 134
C7 BBs 134
C8 CCBs 136
C9 ACEIs 138
C9 ARBs 140
Anatomical Therapeutic Chemical (ATC) classification 143
APPENDIX B 145
Bibliography 145
Hypertension management guidelines 145
JNC 7 145
ESH/ESC 145
WHO/ISH 145
BHS-IV 145
References 146
Report methodology 148
General 148
Japan sales data 148
Key opinion leaders 148
About Datamonitor 149
About Datamonitor Healthcare 149
About the Cardiovascular Disease analysis team 150
Disclaimer 151
Glossary 152
APPENDIX C – MARKET FORECAST DATA 153
US forecasts 153
Japan forecasts 158
France forecasts 162
Germany forecasts 167
Italy forecasts 172
Spain forecasts 177
UK forecasts 182
M5EU forecasts 187
Global forecasts 194
Other selected research from the 'Commercial Insight' category:
Commercial Insight: Cytotoxics - Generic Adversity Facing Major Cytotoxics
Commercial Insight: Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market
Other selected research from the 'Cardiovascular' category:
Pipeline Insight: Antihypertensives - Together We Stand, Divided We Fail
Pipeline Insight: Antithrombotics - Anticoagulants and Antiplatelets Have Blockbuster Potential